Polymer Factory (POLYMER) Q3 2025 earnings summary

Executive summary

• Secured strategic orders and deliveries to leading biopharmaceutical and energy companies, highlighting growing commercial traction.

• Granted patents for Spherical and Dendritic Nanogel technologies in multiple European countries, strengthening IP portfolio.

• Entered supply agreements with global leaders and expanded collaborations, notably with Bruker and Merck Sigma Aldrich.

• Completed a directed share issue and received SEK 2.05 million from full exercise of warrants, boosting working capital.

Financial highlights

• Q3 2025 net sales were KSEK 431, down 23% year-over-year; year-to-date net sales rose 40% to KSEK 1,628.

• Q3 loss reduced to KSEK -563 from KSEK -931 year-over-year; year-to-date loss improved to KSEK -1,608 from KSEK -3,491.

• Cash flow for Q3 was KSEK 1,097, mainly due to new share issues; cash and bank at period end was KSEK 2,727.

• Equity/assets ratio improved to 80% from 74% year-over-year.

• Basic earnings per share for Q3 was SEK -0.04, improved from SEK -0.09 year-over-year.

Outlook and guidance

• Management remains positive for the remainder of 2025 and into 2026, citing strong customer validation and expanding market applications.

• Ongoing commercial outreach and structured engagement with potential customers in North America and Europe.